<DOC>
	<DOC>NCT02096172</DOC>
	<brief_summary>The objective of this study is to evaluate the impact of pharmacogenomic aspects of drug metabolism on the measurement of drug and drug metabolites on urine drug testing (UDT).</brief_summary>
	<brief_title>Urine Toxicology With Pharmacogenomic Interpretation Assay: UTOPIA</brief_title>
	<detailed_description />
	<criteria>Able to provide written informed consent Pharmacogenomic testing within the last 60 days Planned UDT Subject has chronic renal dysfunction, Chronic Kidney Disease Stage 4 or 5 Subject has a history of abnormal hepatic function within the last 2 years (INR &gt;1.2 not attributable to anticoagulant medications, AST or ALT &gt;1.5x normal, or suspected cirrhosis) Subject has a history of malabsorption (short gut syndrome); Subject has a history of any gastric or small bowel surgery; Subject is currently hospitalized; Subject is currently receiving intravenous medication.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>